Patent strengthens Metagenics' portfolio

- Last updated on GMT

Related tags: Nutrition

Metagenics has been awarded a new patent for the specific
combination of nutrients found in its Inflavonoid Intensive Care
product, a natural nutritional supplement claimed to relieve minor
pain and promote healthy joints and muscle tissue.

California-based nutrition company Metagenics has been awarded a new patent for the specific combination of nutrients found in its Inflavonoid Intensive Care product, a natural nutritional supplement claimed to relieve minor pain and promote healthy joints and muscle tissue.

Inflavonoid Intensive Care is suitable for individuals whose joints and/or muscles are affected by physical stressors such as repetitive or high impact motion, heavy or incorrect lifting, poor posture, and a typically inactive lifestyle.

Nearly all Americans will experience minor muscle and/or joint pain during some period of their life. And with growing concern over gastrointestinal (GI)-related side effects from various conventional approaches, every healthcare practitioner should be aware of the available options, explained Metagenics in a statement.

Inflavonoid Intensive Care consists of a blend of boswellia, ginger, turmeric, and cayenne pepper - phytonutrients that inhibit the enzymes involved in prostaglandin synthesis and support healthy, balanced eicosanoids (hormone-like compounds such as prostaglandins and leukotrienes). In particular, the formula contains boswellic acids which can inhibit leukotriene synthesis. Cayenne pepper is traditionally used to support the circulatory and digestive systems and is thought to possess antioxidant properties.

Inflavonoid Intensive Care also includes lemon bioflavonoid complex, quercetin, and vitamin C to provide the body's connective tissues with antioxidant protection from free radical damage. The company claims that in advanced cell-line testing conducted at Metagenics' MetaProteomics research center, Inflavonoid Intensive Care has been shown to effectively inhibit PGE2 (an eicosanoid associated with minor pain) production while exhibiting a high level of predicted GI safety.

"Many companies have explored the use of traditional herbal remedies for relieving minor pain and promoting healthy eicosanoid synthesis,"​ explained Jeffrey S. Bland, president and chief science officer of Metagenics. "Metagenics has pioneered innovative process improvements to help improve safety and efficacy by standardizing premium-quality herbs with a long history of safe use in humans."

The company said it expected the news to strengthen its position as a leading provider of high quality nutraceuticals and medical foods.

Inflavonoid Intensive Care is available exclusively through physicians and other licensed healthcare practitioners.

Related topics: Markets

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars